Office Action Predictor
Application No. 17/780,984

Pharmaceutical Compositions, Formulations And Methods For The Treatment Of Retinoblastoma

Final Rejection §112
Filed
May 29, 2022
Examiner
DAVIS, BRIAN J
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Oxular Limited
OA Round
2 (Final)
85%
Grant Probability
Favorable
3-4
OA Rounds
1y 11m
To Grant
69%
With Interview

Examiner Intelligence

85%
Career Allow Rate
1317 granted / 1549 resolved
Without
With
+-15.7%
Interview Lift
avg trend
1y 11m
Avg Prosecution
46 pending
1595
Total Applications
career history

Statute-Specific Performance

§101
4.0%
-36.0% vs TC avg
§103
15.9%
-24.1% vs TC avg
§102
19.4%
-20.6% vs TC avg
§112
43.6%
+3.6% vs TC avg
Black line = Tech Center average estimate • Based on career data

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restriction The examiner notes for clarity of the record that inventor has added new claims 36-44. These new method claims are encompassed by non-elected Group III. However, the composition claims of elected Group I having been found allowable vide infra, the method claims of Group III have been rejoined. (But note the new 112(b) rejection of new claim 41 below.) 112 Rejections Withdrawn The rejections of claims 13 and 34 under 35 USC 112(b) or 35 USC 112 (pre-AIA ), second paragraph, outlined in the previous Office Action, have been overcome by inventor’s amendment. The amendment clarifies the claims as appropriate. Claim Rejections - 35 USC § 112, NEW The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 41 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, the claim recites the broad recitation “…semisynthetic derivatives of podophyllotoxin…”, and the claim also recites “…(etoposide)…” which is the narrower statement of the range/limitation. The claim is considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. 102 Rejections Withdrawn The first listed rejection of claim 1 under 35 USC 112(a)(1), outlined in the previous Office Action, has been overcome by inventor’s amendment. The amendment narrows the scope of the claimed subject matter such that it no longer reads on the cited art. The rejection of claims 1, 2, 4 and 8 under 35 USC 112(a)(1), outlined in the previous Office Action, has been overcome by inventor’s amendment and arguments. With respect to claim 2, the amendment cancels the claim. With respect to the remaining claims, inventor’s amendment and arguments have been carefully considered and are persuasive. The rejection of claims 1, 2, and 4 under 35 USC 112(a)(1), outlined in the previous Office Action, has been overcome by inventor’s amendment and arguments. With respect to claim 2, the amendment cancels the claim. With respect to the remaining claims, inventor’s amendment and arguments have been carefully considered and are persuasive. The second listed rejection of claim 1 under 35 USC 112(a)(1), outlined in the previous Office Action, has been overcome by inventor’s amendment. The amendment narrows the scope of the claimed subject matter such that it no longer reads on the cited art. Claim Objections Withdrawn The objection to claims 3, 5-7, 9-12, 14 and 35, as being dependent from a rejected base claim but otherwise allowable, is withdrawn. Allowable Subject Matter Claims 1, 3-14, 23-27, 34-40 and 42-44 are allowed. The subject matter of claim 41 would be allowable once the 112 rejection outlined above has been overcome. The following is a statement of reasons for the indication of allowable subject matter: The closest prior art is the prior art of record. As is clear from the record at this point in the prosecution, the cited prior art does not teach, show, suggest or make obvious the instant composition and its method of use. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN J DAVIS whose telephone number is (571)272-0638. The examiner can normally be reached M-F 8:30-5:00 PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush, can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN J DAVIS/Primary Examiner, Art Unit 1614 2/1/2026
Read full office action

Prosecution Timeline

May 29, 2022
Application Filed
Oct 05, 2025
Non-Final Rejection — §112
Dec 09, 2025
Applicant Interview (Telephonic)
Dec 09, 2025
Examiner Interview Summary
Jan 06, 2026
Response Filed
Feb 01, 2026
Final Rejection — §112
Mar 30, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology. Study what changed to get past this examiner.

Patent 12594226
COMPOSITION FOR AMELIORATING SKIN CONDITION
2y 5m to grant Granted Apr 07, 2026
Patent 12594257
MEANS AND METHODS FOR IMPROVING ANTI-TUMORAL EFFICACY OF TRANSMEMBRANE CHANNEL PROTEIN BLOCKERS
2y 5m to grant Granted Apr 07, 2026
Patent 12594242
LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS
2y 5m to grant Granted Apr 07, 2026
Patent 12595280
PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS
2y 5m to grant Granted Apr 07, 2026
Patent 12576107
METHODS OF TREATING CHRONIC INFLAMMATORY DISEASES
2y 5m to grant Granted Mar 17, 2026

AI Strategy Recommendation

Click below to generate an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
85%
Grant Probability
69%
With Interview (-15.7%)
1y 11m
Median Time to Grant
Moderate
PTA Risk
Based on 1549 resolved cases by this examiner